Efficacy News and Research

RSS

ATCC announces new award from BARDA to provide centralized storage and bioprocessing services for Project NextGen

ATCC, the world’s premier biological materials management and standards organization, today announced a five-year, $87 million award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support the development of next-generation medical countermeasures (MCMs) to protect Americans from public health security threats such as coronaviruses.

From ATCC 5 Jan 2024

Metabolically armored CAR-T cells demonstrate lasting efficacy against solid tumors

At EPFL's School of Engineering, Professor Li Tang's Laboratory of Biomaterials for Immunoengineering has made significant strides in cancer treatment research.

4 Jan 2024

Computerized cognitive training shows promise in enhancing memory for dementia patients

Study systematically reviews and meta-analyzes the impact of computerized cognitive training (CCT) on memory functions in patients with mild cognitive impairment or dementia, highlighting the benefits of both supervised and unsupervised CCT.

4 Jan 2024

Gut microbes revealed as key players in liver disease solutions

In the editorial published on 4 September 2023, in the "gut-liver axis" special issue of the journal Hepatobiliary & Pancreatic Diseases International, Dr. Jian-Gao Fan and Dr. Lu Jiang from Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine provided a comprehensive elucidation of the pivotal role of gut microbiota in various liver diseases.

4 Jan 2024

Gut microbiome plays a role in immune response to mRNA COVID vaccines

Researchers from Karolinska Institutet in Sweden have discovered that the gut microbiome can influence how well people respond to mRNA COVID vaccines.

4 Jan 2024

PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease

Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.

From PharmaKure 4 Jan 2024

New compound effective against bacterial species resistant to multiple classes of existing antibiotics

Recent studies by Zampaloni et al. and Pahil et al. published in the journal Nature describe a novel method of inhibiting the growth of Gram-negative bacteria such as Acinetobacter using antibiotics consisting of macrocyclic peptides that target the bacterial protein bridge machinery that transports lipopolysaccharides from the cytoplasm to the outer membrane.

4 Jan 2024

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Study demonstrates that combining dapagliflozin and semaglutide significantly improves glycemic control and other health parameters in type 2 diabetes patients, outperforming dapagliflozin alone.

3 Jan 2024

Natural compounds show promise in modulating heme breakdown, offering new therapeutic avenues

Study explores the impact of natural compounds on bilirubin production and heme catabolic pathway modulation, highlighting their potential in treating neurodegenerative and cardiovascular diseases.

3 Jan 2024

$4.9 million grant awarded to build EndO-trial consortium for improving the lives of Crohn's patients

Cleveland Clinic and the University of Western Ontario have been awarded a $4.9 million grant from Helmsley Charitable Trust to build a consortium to develop clinical trial outcome tools for patients with Crohn's disease and permanent ileostomy.

3 Jan 2024

Existing beta blocker investigated as novel sickle cell therapy

A beta blocker typically used to treat heart problems, hemangioma, migraines and anxiety could be a new therapeutic for patients with sickle cell disease. Researchers led by Ankit A. Desai, MD, associate professor of medicine at the Krannert Cardiovascular Research Center (KCVRC) at Indiana University School of Medicine, have been awarded a $3 million grant by the U.S. Department of Defense to evaluate the efficacy of this drug.

3 Jan 2024

New synthetic antibiotic found to be more effective than established drugs against 'superbugs'

A new synthetic antibiotic developed by University of Liverpool researchers is shown to be more effective than established drugs against 'superbugs' such as MRSA, a new study shows.

3 Jan 2024

New Pfizer/BioNTech vaccine variant shows enhanced protection against COVID-19 hospitalization

Study demonstrates that the BNT162b2 SARS-CoV-2 XBB1.5 variant-modified vaccine significantly reduces the risk of COVID-19-related hospitalizations and ambulatory visits, outperforming previous vaccine versions in the face of evolving virus strains.

2 Jan 2024

RSV vaccines would dramatically reduce disease burden if widely adopted like flu shots

Respiratory syncytial virus (RSV) vaccines recently approved for people 60 and older would dramatically reduce the disease's significant burden of illness and death in the United States if they were widely adopted like annual influenza vaccines, a new study has found.

2 Jan 2024

New AI tool spotlights hidden cancers for better diagnosis

A new artificial intelligence tool that interprets medical images with unprecedented clarity does so in a way that could allow time-strapped clinicians to dedicate their attention to critical aspects of disease diagnosis and image interpretation.

2 Jan 2024

Brain receptor discovery opens door to new therapies for addiction and mental health

Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenapine, a possible therapeutic target for substance use and neuropsychiatric disorders.

2 Jan 2024

Study identifies α-MSH as therapeutic candidate for corneal endothelial disease

Findings from a pioneering study in The American Journal of Pathology, published by Elsevier, reveal that administration of the neuropeptide α-melanocyte-stimulating hormone (α-MSH) promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.

2 Jan 2024

Angelica gigas extract emerges as a potential treatment for vascular disease

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 23, entitled, "Angelica gigas extract inhibits acetylation of eNOS via IRE1α sulfonation/RIDD-SIRT1-mediated posttranslational modification in vascular dysfunction."

28 Dec 2023

Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

28 Dec 2023

New non-steroidal anti-inflammatory can inhibit the cytokine storm and preserve innate immunity

Very early in the COVID-19 pandemic clinical trials in patients hospitalized with COVID-19 confirmed that corticosteroids like dexamethasone reduced mortality, but they were harmful when applied at the first COVID-19 symptoms, due to the weakening of innate antiviral immunity, leading to delayed viral clearance and adverse outcomes in severe viral pneumonias.

28 Dec 2023

Efficacy News and Research

ATCC announces new award from BARDA to provide centralized storage and bioprocessing services for Project NextGen

Metabolically armored CAR-T cells demonstrate lasting efficacy against solid tumors

Computerized cognitive training shows promise in enhancing memory for dementia patients

Gut microbes revealed as key players in liver disease solutions

Gut microbiome plays a role in immune response to mRNA COVID vaccines

PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease

New compound effective against bacterial species resistant to multiple classes of existing antibiotics

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Natural compounds show promise in modulating heme breakdown, offering new therapeutic avenues

$4.9 million grant awarded to build EndO-trial consortium for improving the lives of Crohn's patients

Existing beta blocker investigated as novel sickle cell therapy

New synthetic antibiotic found to be more effective than established drugs against 'superbugs'

New Pfizer/BioNTech vaccine variant shows enhanced protection against COVID-19 hospitalization

RSV vaccines would dramatically reduce disease burden if widely adopted like flu shots

New AI tool spotlights hidden cancers for better diagnosis

Brain receptor discovery opens door to new therapies for addiction and mental health

Study identifies α-MSH as therapeutic candidate for corneal endothelial disease

Angelica gigas extract emerges as a potential treatment for vascular disease

Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

New non-steroidal anti-inflammatory can inhibit the cytokine storm and preserve innate immunity

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News